Many Long Covid and more recently ME/CFS sufferers have turned to natural clot busters (nattokinase, lumbrokinase) since new studies have revealed that many with these diseases have microclots. A few words on their dosing, efficacy and safety. 🧵
Funnily, nattokinase is not a kinase; instead, it is a serine protease. Proteases are enzymes that cleave (break) peptide bonds in proteins. Another example of a serine protease is tissue plasminogen activator (tPA). tPA cleaves plasminogen to plasmin and plasmin dissolves clots.
This double-blind, placebo-controlled crossover study in 12 young & healthy Japanese men found that a single 2000 FU dose of NK activated multiple fibrinolytic & anti-thrombotic pathways: aPTT ⬆️, D-dimer ⬆️ & tPA activated. ncbi.nlm.nih.gov/pmc/articles/P…
However, this larger RCT from 2021 concluded that after a median 3 yrs, daily 2000 FU NK showed no significant effect on blood coagulation and fibrinolysis factors, blood pressure or any other tested labs, & didn't decrease pubmed.ncbi.nlm.nih.gov/33843667/
SAFETY:
My primary worry = bleeding. While study 1 does not assess bleeding risk, all the fibrinolysis/coagulation parameters remained in normal range following NK administration, which is promising. However, that study only looked at one single dose.
SAFETY, cont
The 2021 NK atherothrombotic prevention study (study 2 above) compared daily 2000 FU NK to placebo for a median of 3 yrs, not just 1 single dose. They did not report any adverse effects or bleeding, but of course, they also reported no efficacy whatsoever.
SAFETY, cont
"Consumption of 10 mg/kg-day nattokinase for 4 weeks was well tolerated in healthy human volunteers...Oral consumption of nattokinase [appears] of low toxicological concern."
2000 FU = ~100 mg
60 kg x 10 mg/kg = 600 mg NK = 12,000 FU max dose pubmed.ncbi.nlm.nih.gov/26740078/
This RCT examined the effects of NK on blood pressure. Unlike the above 2021 study which showed no effect on BP, here, NK induced a statistically significant decrease in BP after only several weeks on 2000 FU NK daily.
DOSING:
It appears that 2000 FU once daily is the most clinically studied. In this 2013 NK pharmacokinetics study (see below), pts took one dose of 2000 FU NK following baseline blood samples, then returned at 2, 4, 8, 12, 24, and 48 hours post-dose for subsequent blood draws.
Peak serum levels of NK were observed ~13.3 h ± 2.5 h post-dose. Dosing interval therefore may be 12-24 hours (2000 FU once daily or 2000 FU every 12 hrs in more aggressive dosing). pubmed.ncbi.nlm.nih.gov/23709455/
LUMBROKINASE
Interestingly, lumbrokinase is named after the genus name of earthworm: lumbrokinase = a group of fibrinolytic enzymes isolated & purified from earthworms.🪱 Lumbrokinase's mechanisms of action are depicted here (similar to NK).
SAFETY (lumbrokinase)
This study explored the efficacy and safety of lumbrokinase in the treatment of acute & moderate risk PE. Authors compared lumbrokinase + heparin + warfarin vs heparin + warfarin and found similar safety & better efficacy. pubmed.ncbi.nlm.nih.gov/29093246/
Overall, nattokinase seems more studied than lumbrokinase. I'd personally feel more comfortable trying nattokinase for this reason. I wouldn't combine w/ aspirin. However, everyone is different based on their individual medical history, medications, & risk-benefit analysis!
According to Stephen Buhner in his book Herbal Antivirals, lumbrokinase is 30 times more potent than nattokinase and 300 times more potent than serrapeptase. Serrapeptase is a weaker fibrinolytic but has other benefits like anti-inflamm & removal of cellular debris & toxins.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Important 2016 study found that spironolactone, a prescription drug normally used for heart failure, showed anti-EBV activity via inhibition of an essential EBV protein SM, which preferentially increases expression of specific EBV genes. 🧵pnas.org/doi/10.1073/pn…
Finally a tiny study in 2020 investigated the effects of spironolactone in 21 ME/CFS pts with "positive EBV serology." Somehow the authors were finalists in "Best Poster Prize in Adult Medicine," but the poster is poorly written & provides little info. onlinelibrary.wiley.com/doi/10.1111/im…
The open-label study examined 17 females & 4 males. 5 dropped out due to intolerability. The authors state that of the 16 who completed the study, "5 had no more CFS and all the rest improve in fatigue & general symptoms." 🤔
Unfortunately, luteolin is not greatly bioavailable, and there is potential for drug interactions (as there are for many other common Long Covid supplements) due to CYP3A4 inhibition. However, bioavailability is enhanced with lipid formulations.
During the lytic cycle, EBV expresses deleterious proteins. Several supplements inhibit EBV’s lytic cycle by targeting some of these harmful proteins. Here I will examine the most promising supplements, citing evidence-based dosing, efficacy, & safety.
First up…EGCG.
EGCG, a potent catechin & antioxidant found in green tea, inhibits the initiation of EBV lytic cascade & expression of lytic proteins at concentrations >50 μM (µmol/L). EGCG inhibits the transcription of immediate-early genes, Rta, Zta, & EA-D. doi.org/10.1016/S0006-…
1) nirmatrelvir = 3CL protease inhibitor (like Tollovid) 2) ritonavir: boosts nirmatrelvir by inhibiting an enzyme called CYP3A4
Any medications that are significantly metabolized by CYP3A4 -or- CYP3A4 substrates interact w Paxlovid.
1/x
👉If medication inhibits CYP3A4, this will ⬆️ nirmatrelvir exposure & potentially boost it too high
👉If medication is a major CYP3A4 substrate, then ritonavir may inhibit its metabolism ➡️ potential overdose, requiring a dose reduction or discontinuation (ex: Simvastatin)
2/x
👉If medication is a prodrug (i.e., it needs CYP3A4 to activate itself), ritonavir will inhibit that activation and cause the drug to build up (ex: hydrocodone)
👉If med induces CYP3A4, this will decrease nirmatrelvir exposure & ⬇️ antiviral effects (ex: St. John's Wort)
3/x
Due to concerns about liver toxicity in Tollovid, I've been reading about pyrrolizidine alkaloids (PA) in various herbs. PAs are toxic to the liver and can cause VOD among other issues. I wanted to *very roughly* estimate the PA dose in the total daily Tollovid dose.
First I looked up the elimination of PAs. It's 80% eliminated via feces & urine. Conveniently, this is similar to an estimation that gromwell root (GR) may be eliminated at 80% via same routes.
I tried to find how much GR is in Tollovid, but this info is proprietary. I looked over the patent where it merely stated the ratio for GR to phospholipids was anywhere from 1:10 to 10:1, a huge range! Thus I chose a conservative 1:1 for my calculations (50% GR, 50% excipients).